Human Papillomavirus Testing with Hybrid Capture II and DNA Chip

Abstract

The detection of high-risk human papilloma virus (HPV) allows us to predict the presence and future development of cervical intraepithelial lesion. In this study, we compared Hybrid Capture Ⅱ and DNA chip methods for detection of HPV in cervical swab samples. And we evaluated the clinical efficacy and diagnostic performance of HPV DNA chip and Hybrid Capture II for detecting HPV in cervical neoplastic lesions. Seventy four patients were classified into three groups according to their histologic diagnosis : Group I(nonspecific chronic cervicitis), Group II(low-grade squamous intraepithelial lesion (SIL) ; koilocytosis, and mild dysplasia), and Group III(high-grade SIL;, moderate, severe dysplasia and in situ carcinoma). Cytologic diagnosis were based on the Bethesda System. Hybrid Capture II and DNA chip methods were performed to detect HPV. In 41 of the 74 cervical samples (55.4%), HPV DNAs were detected by Hybrid Capture II. In Group III, HPV-positive cases were detected in 15 (20.3%) of 74 patients by Hybrid Capture II. 25 patients with ASCUS cytology were histopathologically examined : 9 cases (36%) were Group II. In 18 patients with low-grade SIL cytology, 13 cases (72.2%) were Group II and 3 cases (16.7%) were Group III. 12 cases (92.3%) were Group III of 13 patients with high-grade SIL cytology. The sensitivity of each test was 82% in Hybrid Capture II and 53.9% in DNA chip test. And the specificity was 74.3%, 85.7% in Hybrid Capture II and DNA chip. In conclusion, Hybrid Capture II test is more sensitive than DNA chip in detecting women with cervical neoplastic lesions. Especially, in diagnosing of ASCUS, Hybrid Capture II test is more sensitive. Therefore, Hybrid Capture II test for cancer-associated HPV DNA is a viable option in the management of women with ASCUS.